11/16/26
Telesis Bio (TBIO) Thesis The company's recent performance and negative cash flow have raised concerns about its sustainability and ability to scale operations effectively.
★ Analysts see FY2025 revenue reaching $10M — +4.3% growth in a single year.
What Moves the Stock 01 Adoption rates of BioXp™ technology in commercial applications 02 Partnership announcements with major biotech firms 03 Regulatory approvals for new applications in gene therapy 04 Market demand for synthetic biology solutions 05 DNA synthesis services - 70% 06 Consumables and reagents - 20% 07 Collaborative research agreements - 10% 08 Growth in synthetic biology applications -0.0 0.0 0.0 0.0 0.1 0.01 TBIO Daily 0.01 Jun '26 Aug '26 Sep '26 Nov '26
My Notes "Management has indicated that achieving profitability remains a significant challenge in the current market environment." Moat: The proprietary nature of the BioXp™ technology provides a moderate level of competitive advantage… growth - Investors are likely attracted to the potential for rapid revenue growth in the biotech sector. Rising interest rates could increase financing costs for R&D, potentially slowing down expansion plans and affecting valuation multiples. Watch on earnings: Adoption rate of BioXp™ technology, Gross margin percentage, Customer retention rates. One Sentence Summary: Telesis Bio: the story is balanced — adoption rates of bioxp™ technology in commercial applications.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.